Search Results
Your search for Charlotte Bath matches 21 pages
Showing 1 - 21Hormone Combination Therapy May Increase Risk of Breast Cancer in African American Women
The use of combination therapy with estrogen plus progestin, previously shown to be associated with an increased incidence of estrogen receptor–positive breast cancer in postmenopausal women in studies based largely on white women, has been shown to increase this type of breast cancer...
Shorter Delays Between Diagnosis, Surgery, and Chemotherapy Initiation May Improve Survival in Breast Cancer
The survival benefits of reducing the time to surgery following a diagnosis of breast cancer, and time to initiation of adjuvant chemotherapy following surgery were outlined in two articles and an accompanying editorial in JAMA Oncology. Analyzing two independent population-based studies with a...
Some Diagnostic Variability in Interpreting Breast Biopsy Slides
Pathologists would disagree about 8% of the time when interpreting a single breast biopsy slide, with more overinterpretation than underinterpretation in discordant cases, according to an analysis combining results from the B-Path (Breast Pathology) study with data on the prevalence of breast...
Geriatric Assessment Is Key to Treatment Decisions for Patients 80 Years and Older With Breast Cancer
A review of major studies and the current literature underscored the role of geriatric assessment in making treatment recommendations for patients aged 80 years and older with early and metastatic breast cancer. The review was reported by Shachar et al in the Journal of Oncology Practice. The...
Expect Questions and Perhaps Unrealistic Expectations
A recent study reporting the absolute 20-year survival benefit from contralateral prophylactic mastectomy was less than 1% for women with stage I and II breast cancer without BRCA mutations runs counter to common perceptions about the risk of contralateral breast cancer among these women and the...
Shift Over Time in Treatment Patterns of Ductal Carcinoma in Situ
An evaluation of national treatment trends for ductal carcinoma in situ from 1991 to 2010 and their impact on survival revealed “a substantial shift in locoregional treatment patterns for ductal carcinoma in situ,” Mathias Worni, MD, of Duke University Medical Center, Durham North...
To Optimize Tamoxifen Use Among Premenopausal Women With Breast Cancer, Include Access to Fertility-Preservation Options
A multivariable analysis of clinical factors associated with tamoxifen use among premenopausal women with hormone receptor–positive breast cancer showed that fertility preservation was a significant factor and “the only predictor of both noninitiation and early cessation” of...
Diagnosis of Additional Small Breast Cancers Suggests Screening Mammography May Lead to Overdiagnosis
A study of screening mammography across U.S. counties found that “the clearest result of mammography screening is the diagnosis of additional small cancers” but without a “concomitant decline in the detection of larger cancers, which might explain the absence of any significant...
Improved Prognosis for Patients With Estrogen Receptor–Positive Breast Cancer With Large Reductions in Mammographic Density After Tamoxifen Initiation
Improved prognosis for women with estrogen receptor–positive breast cancer who experience a large reduction in mammographic density following the initiation of tamoxifen treatment extends to premenopausal as well as postmenopausal women, researchers reported in the Journal of the National...
Emergency Room Visits and Hospitalizations Are Common Among Women With Early Breast Cancer Receiving Chemotherapy
Emergency room visits and hospitalizations are common among patients with early breast cancer receiving chemotherapy, particularly among those receiving a regimen containing docetaxel, according to a report by Enright et al in the Journal of Oncology Practice. “In this population-based cohort ...
Are Physicians Choosing Wisely When Imaging for Distant Metastases in Early-Stage Breast Cancer?
Patients with early-stage breast cancer still undergo imaging for distant metastases despite evidence-based local, national, and international guidelines, and a recommendation from ASCO to avoid such imaging, according to a retrospective review of staging imaging for distant metastases in patients...
Almost Half of Women Taking Tamoxifen for Primary Prevention of Breast Cancer Discontinue Use Before 5 Years
After 4.5 years of taking tamoxifen for primary prevention of breast cancer, 46% of women discontinued use, according to research conducted within the Sister Study, a prospective cohort of women who had a sister who had been diagnosed with breast cancer but did not have breast cancer themselves....
About 25% of Patients Undergoing Breast-Conservation Surgery for Stage 0 to II Carcinoma Have Subsequent Surgery
“Approximately one-fourth of all patients who undergo initial breast-conservation surgery for breast cancer will have a subsequent operative intervention,” concluded a study published online in JAMA Surgery. “The rate of repeat surgeries varies by patient, tumor, and facility...
Neoadjuvant Chemotherapy Plus Two Anti-HER2 Agents Optimal for HER2-Positive Breast Cancer
For women with human epidermal growth factor receptor 2 (HER2)-positive breast cancer, combining two anti-HER2 agents with chemotherapy is the most effective treatment modality in the neoadjuvant setting, according to a meta-analysis published in the Journal of the National Cancer Institute. The...
Comorbidity Associated With Shorter Overall Survival but Not With Time to Relapse or Toxicity in Older Women on Adjuvant Chemotherapy
In the Cancer and Leukemia Group B (CALGB) 70103 study, comorbidity was associated with shorter overall survival among older women with early-stage breast cancer and good functional status receiving adjuvant chemotherapy. “The presence of four or more conditions appeared to be a threshold for ...
ASCO 2014: Goserelin Helps Preserve Fertility Among Women Receiving Chemotherapy for Hormone Receptor–Negative Breast Cancer
Adding goserelin (Zoladex) to standard chemotherapy may be an effective method of preserving fertility among women with early-stage hormone receptor–negative breast cancer, according to findings from a federally funded phase III clinical trial. In the S0230/POEMS study, reported at the 2014...
ASCO 2014: Women With Breast Cancer and Bone Metastasis Can Safely Scale Back Frequency of Zoledronic Acid Dosing
Findings from a phase III randomized study suggest that women with breast cancer and bone metastasis who have received at least nine doses of zoledronic acid over the previous year can safely scale back dosing from every 4 weeks to every 12 weeks without compromising the effectiveness of the...
ASCO 2014: Adding Lapatinib to Adjuvant Trastuzumab Does Not Improve Outcomes in Early-Stage HER2-Positive Breast Cancer
A large phase III study, ALTTO (Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation), found no statistically significant differences in 4-year disease-free survival among women with early HER2-positive breast cancer who received adjuvant treatment that combined the HER2-targeted drugs...
ASCO 2014: Adjuvant Exemestane With Ovarian Function Suppression Better at Preventing Breast Cancer Recurrence Than Tamoxifen
A joint analysis of two phase III trials demonstrated that the aromatase inhibitor exemestane more effectively prevents breast cancer recurrences than tamoxifen when either was given with ovarian function suppression to premenopausal women with hormone-sensitive cancers. Exemestane plus ovarian...
Mindfulness-Based Stress Reduction Superior to Supportive-Expressive Therapy for Distressed Survivors of Breast Cancer
Mindfulness-based cancer recovery was shown in to be superior to supportive-expressive group therapy decreasing symptoms of stress and improving overall quality of life and social support among survivors of stage I to III breast cancer who were distressed, according to a study reported in Journal...
Some Stage II/III HER2-positive Tumors May Be Treated with Targeted Therapy without Chemotherapy
Results from a multicenter phase II study of patients with locally advanced HER2-positive breast cancer who receive targeted therapy with trastuzumab (Herceptin) and lapatinib (Tykerb) “support the hypothesis that selected patients with HER2-positive tumors may not need...
